Approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback